# The Effects and Safety of 5% Lifitegrast Ophthalmic Solution in Subjects With Dry Eye Disease in Ocular Graft-versus-Host Disease

> **NCT04792580** · EARLY_PHASE1 · COMPLETED · sponsor: **Richard W Yee, MD** · enrollment: 30 (actual)

## Conditions studied

- Graft-versus-host-disease
- Ocular Graft-versus-host Disease

## Interventions

- **DRUG:** Lifitegrast 5% Ophthalmic Solution
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04792580
- **Lead sponsor:** Richard W Yee, MD
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-10-22
- **Primary completion:** 2024-04-30
- **Final completion:** 2024-04-30
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2024-07-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04792580

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04792580, "The Effects and Safety of 5% Lifitegrast Ophthalmic Solution in Subjects With Dry Eye Disease in Ocular Graft-versus-Host Disease". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04792580. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*